Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1159/000438895 http://scihub22266oqcxt.onion/10.1159/000438895 C5345994!5345994!26680582     free     free     free       Endocr+Dev 2016 ; 29 (ä): 230-9 Nephropedia Template TP {{tp|p=26680582|t=2016. Treatment of Peripheral Precocious Puberty |pdf=|usr=}}{{26680582}} gab.com Text Treatment of Peripheral Precocious Puberty JO: Endocr Dev http://www.kidney.de/pget.php?&tw=1&pmid=26680582 #FOAvip There are many etiologies of peripheral precocious puberty (PPP) with diverse manifestations resulting from exposure to androgens, estrogens, or both. The clinical presentation depends on the underlying process and may be acute or gradual. The primary goals of therapy are to halt pubertal development and restore sex steroids to prepubertal values. Attenuation of linear growth velocity and rate of skeletal maturation in order to maximize height potential are additional considerations for many patients. McCune-Albright syndrome (MAS) and familial male-limited precocious puberty (FMPP) represent rare causes of PPP that arise from activating mutations in GNAS1 and the LH receptor gene, respectively. Several different therapeutic approaches have been investigated for both conditions with variable success. Experience to date suggests that the ideal therapy for precocious puberty secondary to MAS in girls remains elusive. In contrast, while the number of treated patients remains small, several successful therapeutic options for FMPP are available. Twit Text FOAVip Treatment of Peripheral Precocious Puberty ????Endocr Dev http://www.kidney.de/pget.php?&tw=1&pmid=26680582 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26680582 #FOAvip English Wikipedia <ref>{{Cite pmid|26680582}}</ref> Treatment of Peripheral Precocious Puberty #MMPMID26680582 Schoelwer M; Eugster EA Endocr Dev 2016[]; 29 (ä): 230-9 PMID26680582show ga There are many etiologies of peripheral precocious puberty (PPP) with diverse manifestations resulting from exposure to androgens, estrogens, or both. The clinical presentation depends on the underlying process and may be acute or gradual. The primary goals of therapy are to halt pubertal development and restore sex steroids to prepubertal values. Attenuation of linear growth velocity and rate of skeletal maturation in order to maximize height potential are additional considerations for many patients. McCune-Albright syndrome (MAS) and familial male-limited precocious puberty (FMPP) represent rare causes of PPP that arise from activating mutations in GNAS1 and the LH receptor gene, respectively. Several different therapeutic approaches have been investigated for both conditions with variable success. Experience to date suggests that the ideal therapy for precocious puberty secondary to MAS in girls remains elusive. In contrast, while the number of treated patients remains small, several successful therapeutic options for FMPP are available. äTreatment of Peripheral Precocious Puberty (epmc).pdf DeepDyve Pubget Overpricing